tiprankstipranks
Amneal Pharmaceuticals Reports Q3 2024 Financial Results
Company Announcements

Amneal Pharmaceuticals Reports Q3 2024 Financial Results

Amneal Pharma ( (AMRX) ) has released its Q3 earnings. Here is a breakdown of the information Amneal Pharma presented to its investors.

Pick the best stocks and maximize your portfolio:

Amneal Pharmaceuticals, Inc. is a global pharmaceutical company that develops, manufactures, and distributes generic and specialty pharmaceuticals primarily within the United States, with a focus on central nervous system and endocrine disorders.

Amneal Pharmaceuticals reported its third-quarter financial results for 2024, showing a net revenue of $702 million, an increase of 13% from the previous year. Despite this revenue growth, the company experienced a GAAP net loss of $0.2 million due to higher interest expenses, marking a shift from the net income reported in the same quarter of 2023.

The company’s generics segment saw a 9% revenue increase, fueled by new product launches and biosimilars. The specialty segment reported a 19% rise in revenue, supported by products in neurology and endocrinology, including the recent launch of CREXONT for Parkinson’s disease. Additionally, Amneal announced strategic partnerships and product expansions to strengthen its market position, including a collaboration with Metsera, Inc. and the acquisition of a high-value biosimilar.

Amneal’s adjusted EBITDA for the quarter reached $158 million, reflecting a 2% increase compared to the same period last year. The company reaffirmed its full-year guidance for 2024, projecting net revenue between $2.70 billion and $2.80 billion, and adjusted diluted earnings per share ranging from $0.57 to $0.63.

Looking ahead, Amneal remains focused on solidifying its growth trajectory through strategic initiatives and continued expansion of its diverse pharmaceutical portfolio. The company aims to create long-term value for stakeholders by leveraging its expertise and expanding its product pipeline.

Related Articles
TheFlyAppeals court sides with Amneal over Teva in inhaler patent fight
TheFlyAmneal resubmits DHE autoinjector NDA, gets FDA approval for exenatide
TheFlyAmneal Pharmaceuticals price target raised to $11 from $9 at Piper Sandler
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App